Current Report Filing (8-k)
November 08 2021 - 4:21PM
Edgar (US Regulatory)
0001709401
false
0001709401
2021-11-04
2021-11-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 4, 2021
RUBIUS THERAPEUTICS, INC.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-38586
|
|
46-2688109
|
(State or other jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
399 Binney Street, Suite 300
Cambridge, MA
|
|
02139
|
(Address of registrant’s principal executive office)
|
|
(Zip code)
|
(617) 679-9600
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading symbol(s)
|
Name
of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
RUBY
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02.
|
Results of Operations and
Financial Condition.
|
On November 8, 2021, Rubius Therapeutics, Inc. (the
“Company”) announced its financial results for the quarter ended September 30, 2021. A copy of the press release issued
in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this Current Report
on Form 8-K, as well as Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange
Act, except as expressly set forth by specific reference in such filing.
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On November 4, 2021, Christina Coughlin, M.D., Ph.D,
notified the Company of her intention to resign as the Company’s chief medical officer, effective as of November 12, 2021, to pursue
another opportunity. In connection with her resignation, Dr. Coughlin has agreed to provide consulting and transition services to the
Company through December 31, 2021.
Item 9.01.
|
Financial Statements and
Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 8, 2021
|
RUBIUS THERAPEUTICS, INC.
|
|
|
|
By:
|
/s/ Jose Carmona
|
|
|
Jose Carmona
|
|
|
Chief Financial Officer
|
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Sep 2023 to Sep 2024